Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2421570 | 1.00 | FAAH (0.34) | FAAHMGLLCCR6ALDH1A1HTT | |
| SCHEMBL27771224 | 0.95 | FAAH (0.40) | FAAHMGLLALDH1A1TSHR | |
| SCHEMBL120122 | 0.93 | ALDH1A1 (0.39) | FAAHMGLLALDH1A1TSHR | |
| SCHEMBL20853080 | 0.93 | ALDH1A1 (0.39) | FAAHMGLLALDH1A1TSHR | |
| SCHEMBL119856 | 0.93 | ALDH1A1 (0.39) | FAAHMGLLALDH1A1TSHR | |
| SCHEMBL1771016 | 0.93 | ALDH1A1 (0.39) | FAAHMGLLALDH1A1TSHR | |
| SCHEMBL9278970 | 0.90 | FAAH (0.39) | FAAHMGLLALDH1A1TSHRCA1 | |
| SCHEMBL6803655 | 0.89 | CA1 (0.32) | CA1CA2CA4 | |
| SCHEMBL5810840 | 0.89 | CA1 (0.32) | CA1CA2CA4 | |
| SCHEMBL486953 | 0.89 | ALDH1A1 (0.38) | FAAHMGLLALDH1A1TSHRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4356894-A1 | SUSTAINABLE PRODUCT WITH MALODORS | Beiersdorf AG (DE) | 2024-04-24 | — | — | EP | claimed |
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| US-20260096991-A1 | BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION | XAMPLA LTD (GB) | 2026-04-09 | — | — | US | disclosed |
| EP-4489592-B1 | BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION | XAMPLA LTD (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250255827-A1 | BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION | XAMPLA LIMITED (GB) | 2025-08-14 | — | — | US | disclosed |
| EP-4593639-A1 | BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION | Xampla Limited (GB) | 2025-08-06 | — | — | EP | disclosed |
| US-20250186960-A1 | BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION | XAMPLA LIMITED (GB) | 2025-06-12 | — | — | US | disclosed |
| EP-3888782-B1 | COATED MICROCAPSULES | NOXELL CORP (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250177298-A1 | EMULSIONS AND A METHOD FOR THEIR PREPARATION | XAMPLA LIMITED (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2025109106-A1 | CORE-SHELL MICROCAPSULES | XAMPLA Ltd. (GB) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025093456-A1 | THIAZOLIDINE-4-CARBOXYLATE PROPERFUMES | FIRMENICH SA (CH) | 2025-05-08 | — | — | WO | disclosed |
| EP-2366014-B1 | PERFUME SYSTEMS | PROCTER & GAMBLE (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2799864-A1 | Method to evaluate fragrance compositions | The Procter and Gamble Company (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2799863-A1 | Method to evaluate fragrance compositions | The Procter and Gamble Company (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140221269-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-08-07 | — | — | US | disclosed |
| US-8754028-B2 | Perfume systems | THE PROCTER & GAMBLE COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| CN-102257119-A | Perfume system | PROCTER & GAMBLE | 2011-11-23 | — | — | CN | disclosed |
| EP-2366014-A2 | PERFUME SYSTEMS | The Procter & Gamble Company (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20100152083-A1 | Perfume Systems | PROCTER & GAMBLE COMPANY, THE | 2010-06-17 | — | — | US | disclosed |
| WO-2009027957-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260096991-A1 | BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION | PCTP, CLK4, MTCL3 | FAAH 2649/4885MGLL 629/4885CCR6 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.